Slide 1: Investor Presentation: Equity Raising
We’re doing medicinal cannabis differently Investor Presentation Equity Raising | 6 November 2024
Slide 2: Disclaimer and important notice (1 of 2)
Disclaimer and important notice (1 of 2) This presentation contains summary information about Rua Bioscience Limited (Rua) and its activities that is current as at the date of this presentation. Information of a general nature The information in this presentation is of a general nature and does not
Slide 3: Disclaimer and important notice (2 of 2)
Disclaimer and important notice (2 of 2) Past performance Investors should note that past performance, including past share price performance, cannot be relied upon as an indicator of (and provides no guidance as to) future Rua performance, including future financial position or share price performa
Slide 4: Pivotal time in Rua Bioscience's journey
Pivotal time in Rua Bioscience‘s journey 1 Accelerating revenue in global markets Having established a capital-light model focused on intellectual property in genetics and regulatory expertise, Rua is now selling products in NZ, Australia and Germany through our distribution partners. The business i
Slide 5: Rua is doing medicinal cannabis differently in the NZ market
Rua is doing medicinal cannabis differently in the NZ market Rua operates in a targeted segment of the market with the lowest capital requirements. This means we can leverage our expertise to deliver scalable value with trusted partners. Rua’s point of difference relative to other NZ cannabis compan
Slide 6: Rua is now at a critical point and requires shareholder support
Rua is now at a critical point in our development and we require shareholder support Proposed $3.1m capital raising critical to Rua‘s Have proved that our commercial model works ongoing business: – Additional funds required to increase working capital (purchase Established critical cultivation,
Slide 7: Rua's genetic provenance
Rua’s genetic provenance The cannabis varieties we source are unique to Rua – Connections to legacy growers provide access to unique varieties and genetics available only to Rua. – Rua has an authentic local impact story: • We have accessed close to 100 illicit varieties from our community. • We cro
Slide 8: Supply and cultivation agreements with highly reputable global partners
Supply and cultivation agreements with highly reputable global partners Canada Denmark Portugal Malta New Zealand Australia International cultivation and Cultivation Kalyx manufacturing Apollo Green footprint reduces our risk of supply disruptions Manufacturing 8
Slide 9: Established high-value branded product range
Established high-value branded product range Stage 1 – Sell branded products into large and established markets Rua has a portfolio of branded products which are achieving sales in key markets now. Based on distribution arrangements recently put in place, sales revenues are expected to grow material
Slide 10: Leading global distribution partners will accelerate growth
Leading global distribution partners will accelerate growth in international markets Nimbus Health – Germany – Highly respected Tier 1 Cannabis wholesaler and manufacturer within Germany. – Fully licensed to undertake international importing and exporting activities. – Now owned by Dr Reddy’s Labora
Slide 11: Go-to-market sales strategy accelerating
Go-to-market sales strategy accelerating Germany New product Germany launched First product New Zealand launched GMP license New Zealand received New product launched FY21 FY22 FY23 FY24 FY25 United Australia Kingdom Established sales Product Germany New Zealand presence launch Agreement with Produc
Slide 12: Targeting meaningful international markets
Targeting meaningful international markets Estimated Market Size Germany ~ $800m • 31t medicinal cannabis imports in 2023 • 12t in Q2CY24 Australia ~ $400m • 42t medicinal cannabis imports in 2023 United Kingdom ~ $60m • 24t medicinal cannabis imported in 2023 • Significant growth expected New Zeala
Slide 13: Sales revenue is accelerating and expected to continue
Sales revenue is accelerating and expected to continue Rua is only targeting large international medicinal cannabis markets as well as Aotearoa, New Zealand. Annual Sales Forecast1 Sales momentum is accelerating with $223k of sales (unaudited) in Q1FY25 vs $86k over entire FY24. Current demand large
Slide 14: Our teams are experts at negotiating with international distributors and regulators
Our teams are experts at negotiating with international distributors and regulators Management Team – We are a leading New Zealand company with a single global brand portfolio that can be showcased in a market with restrictive advertising. Paul Naske Emma McIldowie John Sanders Chief Executive Offic
Slide 15: Rua delivers outsized community impact through targeted programmes
Rua delivers outsized community impact through targeted programmes Com p a ssio na te Pa tie nt Acce ss Prog ra m m e Stud e nt Schola rship Prog ra m m e Leveraging support from partners and Through Rua‘s scholarship programme, assisting local community, Rua are now supporting Te Tairawhiti student
Slide 16: Offer Details
O ffe r De ta ils Offer Size and • 3 for 4 pro-rata renounceable entitlement offer to raise up to $3.1 million Structure • Up to approximately 122.8m new Rua shares to be issued (75% of existing shares on issue) • $0.025 per new share, representing a discount of 47.4% to the 20-day volume weighted a
Slide 17: Offer Timetable
O ffe r Tim e ta b le Announcement of the Offer Wednesday, 6 November 2024 Rights Trading Opens Tuesday, 12 November 2024 (Rights trading commences on the NZX Main Board) Record Date 5pm, Wednesday, 13 November 2024 (for determining eligibility to participate in the offer and entitlements) Opening D
Slide 18: Appendix A: Market Outlook
Appendix A Market Outlook 18
Slide 19: Australia market size
Australia is now one of the larger medicinal cannabis markets in the world. Performance so far – In early 2023 Rua established the appropriate licences and operating structures in Australia to be able to sponsor and take branded products to market. Australia Market size – The first Australian-based
Slide 20: Germany market size
We have launched into Germany at a time when regulatory changes are driving significantly increased demand. Performance so far Germany Market size – Signed distribution agreement with Nimbus Health in April 2020. 1,400 – Launched first dried flower products in April 2023. Initial strong sales revenu
Slide 21: New Zealand market size
Aotearoa New Zealand is our home market and important for our local community and patients. Performance so far New Zealand Market size 60 – Compassionate Access Programme established for Tairawhiti patients in April 2022. Market Size (NZD Millions) 50 – New dried flower product approved February 202
Slide 22: United Kingdom market size
The United Kingdom is a market in its infancy which is projected to grow rapidly. Performance so far – Agreement signed with Target Health in December 2023. – Regulatory requirements underway. UK Market size 3 Units of product (millions) Looking forward – First products expected in market approximat
Slide 23: Appendix B: Key Risks
Appendix B Key Risks RUA
Slide 24: Risks and mitigants
Risks and mitigants Investment into Rua has risks. There is no guarantee of future payments of dividends or returns of capital. An investment into the Company is not risk-free; investors should consider this investment carefully. The Directors strongly recommend that potential investors consult thei
Slide 25: RUA Bioscience
RUA BIOSCIENCE